Association between genetic polymorphisms of the prostaglandin F2α receptor gene, and response to latanoprost in patients with glaucoma and ocular hypertension

Abstract

An association was found between SNPs of the FP receptor gene and the response to latanoprost in patients with glaucoma or OH. The FP receptor genetic polymorphism may influence the degree of IOP reduction by latanoprost in these patients.

Association between SNPs of Metalloproteinases and Prostaglandin F2α Receptor Genes and Latanoprost Response in Open-Angle Glaucoma

“…Schwartz et al 7 reported a relationship between a single nucleotide polymorphism (SNP) at codon 389 in the b-adrenergic receptor gene and a greater response to betaxolol 0.25% (Betoptic; Alcon Laboratories, Fort Worth, TX); this response is related to a SNP at nucleotide 1165 where a substitution G/C results in an arginine/glycine (Arg/Gly) substitution at codon 389, changing the G protein structure near the binding domain, in normal healthy volunteers. Sakurai et al 8,9 reported an association between SNPs and a positive or negative response to latanoprost in healthy Japanese volunteers; SNPs rs3753380 and rs3766355 in the promoter and intron 1 regions of the prostaglandin F2a receptor (PTGFR) gene downregulated expression of the gene after a short course of latanoprost treatment (1 week), resulting in a diminished therapeutic effect.The Latanoprost Study Group (LSG) determined a nonresponse rate of 18%, which was defined arbitrarily as an IOP reduction of less than 15% of the basal IOP after 2 weeks of treatment with latanoprost. 10 The rates of response to latanoprost vary among populations, from 4.1% in an Italian population 11 to 13.5% in American populations.…”

Medical Treatment of Primary Canine Glaucoma

“…In humans, single-nucleotide polymorphisms have been identified in patients who responded well to timolol (>20% IOP reduction, high responders) and in individuals who demonstrated a poor response to latanoprost (nonresponders). 1,2 Although not specifically studied in dogs, clinical experience dictates that this principle holds true for clinical glaucoma patients as well. This may help explain the often conflicting results of various studies evaluating the efficacy of glaucoma drugs in canine patients.…”

PTGFR and SLCO2A1 Gene Polymorphisms Determine Intraocular Pressure Response to Latanoprost in Han Chinese Patients with Glaucoma

“…Meanwhile, the patient's gender correlated with the IOP reduction on day 7, but not on day 30. Sakurai et al 7 and Gao et al 8 found that baseline IOP did not correlate with %ΔIOP. These findings suggest that the key factors related to IOP reduction may be more complicated in patients with high baseline IOP than in patients with low baseline IOP.…”

“…4,5 Two SNPs (rs3753380 and rs3766355) of the prostaglandin F 2α receptor (PTGFR) gene were found to correlate with the response to short-term latanoprost treatment in normal volunteers, 6 and rs12093097 was found to correlate with the response to latanoprost in patients with primary open angle glaucoma (POAG) and ocular hypertension (OH). 7 Similarly, Gao et al 8 also found that rs3753380 and rs3766355 in PTGFR gene may be important determinants of variability in response to latanoprost. However, McCarty et al 9 found no association between SNPs in the PTGFR gene or solute carrier organic anion transporter family 2A1 (SLCO2A1) gene and response to prostaglandin analogs.…”